Kazuhiro Terada
Overview
Explore the profile of Kazuhiro Terada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shigeyasu Y, Harada S, Yoshizawa A, Terada K, Bise R
Annu Int Conf IEEE Eng Med Biol Soc
. 2025 Mar;
2024:1-4.
PMID: 40039994
This paper proposes a semi-and-weak supervised pathological image segmentation method that effectively leverages the pre-recorded long-diameter information of a tumor in clinical as weak supervision. By leveraging the tumor diameter,...
2.
Kabuto T, Menju T, Nishikawa S, Terada K, Yoshizawa A, Date H
Ann Thorac Cardiovasc Surg
. 2025 Jan;
31(1).
PMID: 39842815
Purpose: We aimed to elucidate the efficacy of conventional cisplatin-based adjuvant chemotherapy for patients with lung cancers harboring epidermal growth factor receptor (EGFR) mutation. Methods: This retrospective cohort study included...
3.
Uyama M, Handa T, Uozumi R, Hashimoto S, Taguchi Y, Ikezoe K, et al.
Respir Res
. 2024 Dec;
25(1):442.
PMID: 39719582
Background: The composite physiologic index (CPI) was developed to estimate the extent of interstitial lung disease (ILD) in idiopathic pulmonary fibrosis (IPF) patients based on pulmonary function tests (PFTs). The...
4.
Hamaji M, Ozasa H, Sakamori Y, Terada K, Yoshizawa A, Kikuchi R, et al.
J Thorac Dis
. 2024 Oct;
16(9):6094-6100.
PMID: 39444859
Background: Immune checkpoint inhibitors (ICIs) improved the long-term survival outcomes in patients with advanced non-small cell lung cancer (NSCLC), whereas the role of salvage surgery after ICIs was unknown. The...
5.
Ito H, Yoshizawa A, Terada K, Nakakura A, Rokutan-Kurata M, Sugimoto T, et al.
Mod Pathol
. 2024 Apr;
37(6):100485.
PMID: 38588885
Several studies have developed various artificial intelligence (AI) models for immunohistochemical analysis of programmed death ligand 1 (PD-L1) in patients with non-small cell lung carcinoma; however, none have focused on...
6.
Terada K, Menju T, Date H, Haga H, Yoshizawa A
Thorac Cancer
. 2024 Mar;
15(12):1029-1033.
PMID: 38478955
Most lung carcinomas are subtyped by their morphologies; however, immunohistochemistry is usually performed when it is difficult to determine. The most reliable antibodies for distinguishing lung adenocarcinoma from squamous cell...
7.
Ahmad T, Kawasumi R, Taniguchi T, Abe T, Terada K, Tsuda M, et al.
Nucleic Acids Res
. 2023 Nov;
51(22):12288-12302.
PMID: 37944988
Leading-strand DNA replication by polymerase epsilon (Polϵ) across single-strand breaks (SSBs) causes single-ended double-strand breaks (seDSBs), which are repaired via homology-directed repair (HDR) and suppressed by fork reversal (FR). Although...
8.
Resolution of Eosinophilic Pneumonia after Coronavirus Disease 2019 without Systemic Corticosteroids
Misaki Y, Hayashi Y, Shirata M, Terada K, Yoshizawa A, Sakamoto R, et al.
Intern Med
. 2023 Aug;
62(21):3223-3230.
PMID: 37587039
Pulmonary and extrapulmonary complications after coronavirus disease 2019 (COVID-19) have been major public health concerns during the COVID-19 pandemic. Although post-COVID-19 pulmonary manifestations cover a wide spectrum, eosinophilic pneumonia (EP)...
9.
Terada K, Yoshizawa A, Liu X, Ito H, Hamaji M, Menju T, et al.
Mod Pathol
. 2023 Aug;
36(11):100302.
PMID: 37580019
Neoadjuvant therapies are used for locally advanced non-small cell lung carcinomas, whereby pathologists histologically evaluate the effect using resected specimens. Major pathological response (MPR) has recently been used for treatment...
10.
Nishimura N, Niwamoto T, Arai Y, Nakashima R, Terada K, Yoshizawa A, et al.
Int J Rheum Dis
. 2023 Feb;
26(6):1172-1177.
PMID: 36789793
A 58-year-old man with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5-DM) developed Epstein-Barr virus (EBV)-associated malignant lymphoma as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD) during the combined immunosuppressive therapy of high-dose...